The carbohydrate-deficient glycoprotein (CDG) syndrome typc 1 is a genetic multisystem disorder, characterized by hypoglycosylation of glycoprotcins and presenting with neurologic impairment. In 12 girls and 14 boys, we confirmed the diagnosis of CDG syndrome typc 1 by immune-isoclectric focusing of serum sialotransferrins, and we examined the endocrine status singly or sequentially, including a 16-y follow-up of the index cases, a pair of monozygotic girls. Scrum FSH levels were normal in newborns and prepubertal children, but elevated in female toddlcrs and teenagers, as well as in adolescent males. Scrum LH concentrations displayed an analogous age-dependent pattern. In adolesccnt girls, serum estradiol remained low. FSH bioactivity was low normal, as was the bioactiveii~nmunoreactive FSIl ratio. However, exogenous gonadotropins evoked an estradiol response and induccd ovarian follicular growth. Male patients virilized at puberty; howcver, testicular volume was subnormal. The thyroid axis was hallmarked by thyroid-binding globin deficiency and, during infancy, increased serum TSH concentrations. A subgroup of female patients presentcd hypersomatotropism and/or hyperprolactinemia. During adolescence, the index cases responded to glucagon with normal glycemic, but
exaggerated insulin and paradoxally augmented growth hormone responses. The hypothalamo-pituitary area i~ppcared intact on magnetic rcsonance imaging. Circulating IGF-1 lcvcls werc in the lower normal range and transcortin concentrations decreased.
In conclusion, a study of endocrine aspects of a major glycosylation disorder revealed an age-dependent constellation, including hypcrgonadotropic hypogonadism with deficient FSH rather than LH action; transient hyperthyrotropinemia; inconsistent hyperprolactinemia; hyperglycemia-induccd growth hormone rclease; deficiencies of hormone-binding glycoprotcins and possibly decreased insulin sensitivity, thus pointing to the importance of glycoprotein glycosylation for pediatric endocrinology. Three patients were examined as newborns (age < I mo), five as infants (age 1 mo to 1 y), 14 as toddlcrs (age 1-5 y), eight as childrcn (age 6-9 y), and eight as adolesccnts or young adults (age 12-20 y) .
In all patients, the diagnosis of CDG syndrome type 1 was confirmed in our laboratory by isoelectric focusing of serum sialotransferrins, showing a cathodal shift with significantly decreased tetrasialofraction and increased di-and a-sialofractions (1) .
Standard RIA or immunoradiometric assay techniques were used for determination of serum concentrations of the reported hormones, including prolactin, GH, FSH, LH, TSH, insulin, cortisol, and thyroid hormones; serum IGF-I levels were measured after acid-ethanol extraction (8) (9) (10) .
Dynamic eildocrine studies werc performed in the indcx cases, a pair of monozygotic twin sistcrs, between 2 and 18 y of age (1, 7) . Concomitant 6-h secretory profiles for GH, prolactin, TSH, LH, and FSH were obtained in a newborn CDG patient with polycythemia, by using deconvolution analysis on sequential hormone concentrations in serum samples obtained during an isovolumetric, partial exchange transfusion ( 8 ) . All other data werc derived from spare serum, that had been obtained for different diagnostic purposes.
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Fs" (run.) 1 . r Deconvolution analysis of hormone secretory profiles was performcd according to and by courtesy of Dr. J. D. Veldhuis (University of Virginia, Charlottesville, VA) (11).
FSH bioactivity studies were pcrformed in 1990 by courtesy of Drs. A. J. W. Hsueh and K. Nishimori (University of California San Diego, La Jolla, CA), using the in vitro granulosa cell aromatase bioassay, as previously described (12, 13) .
RESULTS
Gonadal axis. Basal serum concentrations of FSH and LH were age dependent (Fig. 1, left panels) . FSH levels were particularly elevated in female toddlcrs (normal, <5 IUIL) and in female and some male adolescents (normal, <20 IUiL). LH levels were consistently increased in female tccnagers (normal, <20 IUiL).
GnRH (1 pglkg i.v.), administered at the ages of 2 and 13 y to the monozygotic sisters, elicited at both ages a homogeneous hyperresponse of FSH and LH, the resulting serum levels at 13 y being higher than at 2 y (Fig. 1 , upper right panels). Deconvolution analysis of the serum profiles during these tests revealed that the serum half-lives of LH were extremely long (455-755 min; normal, -60 min) and that thc FSH bursts were delayed and very prolonged, the FSH half-lives being 42-256 min (normal, -240 min). PEDIATRIC ENDOCRINOLOG rY OF THE CDG SYNDROME
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Male patients have normally differentiated external genitalia, suggestive of prenatal chorionic gonadotropin bioactivity. Affected boys virilize at puberty, although testicular volume remains small ( 5 5 mL; normal adult, 20-25 mL). Basal serum testosterone concentrations were normally elevated in a 2-moold male infant (11.9 nmol/L) and in four male teenagers (6.7-31.3 nmol/L), indicating endogenous LH bioactivity.
In contrast, serum estradiol levels in four adolescent girls were found to remain in the prepubertal range ( 4 0 pmol/L); ultrasound examination revealed the bilateral presence of ovaria without signs of follicular activity; breast development failed to occur. Basal serum testosterone levels were measured in two of the female teenagers and were elevated (3.5 and 3.8 nmol1L; normal <3.5 nmol/L), whereas the serum androstenedione levels were normal (2.7 and 3.1 nmol/L; normal 2.5-5.0 nmol/L) and the serum dehydroepiandrosterone sulfate concentrations were not suggestive of adrenal zona reticularis hyperfunction (4.6 and 5.6 pmollL; normal 1.3-6.5 pmol1L). Together, the in vivo data obtained in female adolescents with the CDG syndrome are consistent with the concept of an exaggerated LH-driven theca cell function and a lack of FSHdependent granulosa cell function, in spite of the striking availability of immunoreactive FSH.
The administration of low doses of human menopausal gonadotropins (75 IU FSH intramuscularly once daily for 7 d; Humegon, Organon, The Netherlands) to the monozygotic twin sisters at the age of 13 y resulted in a definite ovarian response in one of the girls, as judged by a concomitant rise of serum estradiol to 437 pmol/L, by development of a single ovarian follicle ( Fig. 2 ) and by rapid breast budding. The twin girl responded also, but in a less convincing fashion.
In vitro, using the rat granulosa cell aromatase bioassay, the serum of the aforementioned twins was found to have a low normal FSH bioactivity (71 and 120 IUIL; 80-246 IUIL in age-matched girls with gonadal dysgenesis or bilateral ovariectomy) and a low normal bioactive/immunoreactive ratio (0.15 and 0.21; 0.19-0.69 in the controls). Chromatofocusing analysis revealed no substantial changes in the charge pattern of the bioactive FSH fraction, which eluted at a normal pH (3.8-5.2; 4.0-4.9 for FSH of postmenopausal women).
Thyroid axis. Basal serum TSH levels appear to be age dependent (Fig. 3 , left panel), being elevated in infancy (>h mU/L; normal 0.15-4.6 mUIL) and normal during late childhood and adolescence, the toddlers forming a transition group. Administration of TRH (200 p g i.v.) to the monozygotic twins at the ages of 2, 3, 13, and 17 y also evoked gradually decreasing TSH responses (Fig. 3, right panel) .
Serum TBG concentrations were consistently low for age (n = 15; median, 9.8 mg/L; range, 5.3-16.5 mg/L; normal, 14-24 mg/L), including a measurement at the age of 1 d (13.4 mg/L). Free thyroxine concentrations were low to normal at all ages (n = 10; median, 9.0 pmol1L; range, 4.3-14.3 pmol/L; normal, 9.0-24.5 pmollL).
Prolactin. Basal serum prolactin concentrations were normally elevated (>I00 pg/L) in all three studied newborns and normally low ( < I 5 pg/L) in 22 of the 26 patients examined after the neonatal period. Elevated basal prolactin levels were observed in four female patients, two girls aged 2 y (31 and 39 pg/L) and the monozygotic sisters. In the latter two cases, the basal hyperprolactinemia decreased gradually over a course of 15 y and was sensitive to the release-inhibitory action of exogenous L-dopa (150 mg orally) at the age of 3 y; the response of prolactin to stimulation with TRH (200 p g i.v.) also normalized gradually (normal, <80 pglL) (Fig. 4) .
Growth hormone and insulin. Basal serum GH concentrations were normally low in the 14 examined boys, being < I 0 pg1L in 13 of them, and 13.5 pg/L in the youngest patient, aged 2 mo. In contrast, basal GH levels were (10 pg/L in only four of the 12 girls studied, being augmented (10-58 pg/L) in five of them, and strikingly elevated on threc occasions: 192 and 120 pg/L in different infants aged 1 and 2 mo, and 144 pg/L in one of the twin sisters at the age of 2 y. In the latter three patients, basal GH concentrations <20 pg/L were documented within the 6 mo following.
In the monozygotic pair, the glycemic, GH, and insulin responses to glucagon administration (0.1 mglkg intramuscularly) were examined at the ages of 2, 13, and 17 y (Fig. 5 depicts the results at age 13 y). Thc consecutivc tests consistently resulted in a normal glyccmic rcsponse and a biphasic GH rise with a paradoxally clcvated component during the initial phase of hypcrglycemia (normal, <10 pg/L) and an adequate rcsponse aftcr the decline of glyccmia (normal, 10-40 pg/L). At age 13 y, the insulin response was strikingly augmented (pcak concelltrations of 4234 and 2534 pmol/L; normal, <I440 pmol/L); this insulin hypcrresponsc was not obscrvcd at the agc of 2 y (pcak levels of 144 and 230 pmol/L), but was similar at the age of 17 y. Other endocrine studies. Serum IGF-1 concentrations werc low or low normal in infants and children (n = 15 below age of 9 y; mcdian, 33 pg/L; range, 12-92 pg/L; normal, 77-135 pg/L) and low to normal in adolescents (n = 8; mcdian, 267 pg/L; rangc, 107-437 pg/L; normal, 350-504 pg/L), and appcarcd to be gcnder indcpcndent. Adrenarchc appears to occur normally, as serum dchydrocpiandrosterone-sulfate levcls were low ( c 0 . 2 pmol/L; n = 7) under the age of 6 y, became detectable thereaftcr, and wcre normal during adolescence (n = 5; mcdian, 4.6 pmol/L; range, 1.3-5.6 pmol/L; normal, 1.1-6.8 pmol/L).
Scrum transcortin levels were distinctly low (rz = 5; range 8-25 mg/L; normal range, 32-50 mg/L) and did not altcr bctween thc age of 2 and 17 y in the twins; frcc cortisol concentrations and circulating sex-hormone binding globulin levels wcre found to be normal.
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Figure 5 . Blood glucose, serum GH, and insulin lcvels in monozygotic twin sistcrs (0 and 0 ) with the CDG syndrome typc 1 during a glucagon test (3 mg intramucularly) at the age of 13 y. The glycemic response is normal. GH presents a paradoxical and imprcssivc secretory rcsponse during tlie initial hyperglyccmia, followcd by a second phase of hypcrsecretion, thus yieldiny a pronounced biphasic pattern. Thc insulin rcsponse presents a strikingly clevated amplitude.
In a single 5-d-old polycythemic girl with CDG syndromc type 1, 6-h secretory profiles of FSH, LH, GH, prolactin, and TSH were derivcd during a partial exchange transfusion (Fig.  6 ). FSH and LH concentrations werc undetectably low (<1 U/L) throughout the 6-h period, as in polycythemic but otherwise healthy female newborns (8) . GH displayed a neonatal pattern of cxclusively pulsatile hypersecrction with an interburst intcrval of 60 min and a calculated GH half-life of 27 min, comparable to polycythemic controls (9) . The scrum concentrations of prolactin wcre at the normal neonatal level, but the mode of prolactin releasc was particular, as approxi-PEDIATRIC ENDOCRINOLOGY OF THE CDG SYNDROME S e r u m C o n c e n t r a t i o n S e c r e t o r y R a t e mately 15% of the circulating prolactin was secreted in a pulsatile fashion, whereas prolactin is released by polycythemic controls in an exclusively tonic way (9, 14) . Serum TSH concentrations were in the high normal neonatal range, and TSH was secreted through a combination of tonic and pulsatile release, as in polycythemic control newborns (10) . The mean pulse amplitude, duration, and frequency of TSH secretion were not exceptional, the interburst interval being 136 min, but the TSH half-life was short, namely 25 min (control 56-85 min) (10) . The hypothalamic-pituitary morphology as visualized by magnetic resonance imaging (n = 7) was normal (Fig. 7) . The patients from whom growth data were available (n = 9) presented a height and weight progression at the level of the third percentile for chronologic age [see Jaeken et al. 
DISCUSSION
This report provides a first view on the spectrum of endocrine abnormalities encountered from birth through adolescence in patients with a major disorder of glycoprotein glycosylation, namely the CDG syndrome type l . This spectrum was found to include gender-and age-dependent hypergonadotropic hypogonadism; euthyroidism with transient hyperthyrotropinemia; inconsistent, but impressive hyperprolactinemia and hypersomatotropism; age-dependent insulin hyperresponsiveness to glucagon; low serum levels of hormone-carrier proteins as TBG and transcortin; and prolonged or shortened circulating hormone half-lives, as for LH and TSH, respec- tively. Thus, this complex, heterogeneous and age-dependent entity is the first human endocrinopathy recognized to be based, either directly or indirectly, on glycosylation-related dysfunctions, plausibly including modifications of secretory pathways; modulations of circulating half-lives; perturbations of glycoprotein stability; disequilibria in carrier protein availability and binding; alterations in receptor configuration, binding, and activation; deregulations in autocrine and paracrine actions, and resetting of endocrine control and feedback loops.
DE ZEGHER AND JAEKEN
The hypothalamo-pituitary-gonadal axis was consistently found to be perturbed in the studicd patients, offering a picture of hypergonadotropic hypogonadism. Interestingly, the in vivo bioactivity of LH, which normally has fewer glycosylation sites and carries more sulfated carbohydrates compared with FSH [reviewed in Ronin (15) ], appeared to be less affected than the bioactivity of FSH. In the adolescent twin girls, the reduced in vivo bioactivity of FSH was studied in more detail. The administration of exogenous gonadotropins, primarily cxtracted FSH, promptly elicitcd estrogen secretion and follicular development, suggcstivc of target organ responsiveness. Recently, this phenomenon was also observed in a Japanese girl with CDG syndrome type 1 (16) . Moreover, the irz vitro bioactivity of FSH from thc CDG patients was not severely reduced, whcn examined in a rat granulosa ccll bioassay. Togcthcr, these findings suggest that the strikingly reduced bioactivity of FSH in CDG patients is of multifactorial origin, possibly a combination of minor alterations in the configuration of both hormone and receptor, and in their microenvironment, including LH, inhibins, activins, follistatin, IGF, steroids, and their respective receptors and binding proteins.
Although patients appeared to be cuthyroid throughout the studied age range, basal TSH concentrations and TRH-induced TSH levels were found to be elevated in the youngest children compared with older individuals. At present, the pathophysiologic basis for this observation is uncertain, particularly as the evaluation of the thyroid status in CDG patients is complicated by the coexisting TBG deficiency and potential alterations in the binding of thyroid hormones to this carrier protein. Howcvcr, it is possible that TSH action is more sensitive to appropriate glycosylation of itsclf and/or its receptor during infancy compared with later in life (17, 18) . Furthermore, it is noteworthy that TBG deficiency was already documented in a I-d-old affected newborn, indicating that TBG may be an earlier serum markcr for the disordcr than abnormal transferrin isoforms (1 9).
Hyperprolactincmia was documented in a minority of the femalc patients. The mcchanism underlying this phenomenon and the prolactin hyperresponsiveness to TSH-releasing hormone is hitherto unclear. A decreascd inhibitory action of dopamine may be involved, possibly through decreased hypothalamic dopamine release rather than through diminished pituitary sensitivity to dopamine, as the hyperprolactinemia was suppressible by exogenous L-dopa. However, other mechanisms may interfere; for example, the hypothalamic secretion of TRH could bc augmented, or the function of the activin-A receptor could be defective, resulting in a decreased paracrine inhibition of prolactin release (20, 21) .
Excessively elevatcd serum GH concentrations were detected in some infants, and biphasic GH hyperresponses were repcatcdly observed upon glucagon stimulation in the index cases. Again, the pathogenesis of these exceptional findings is likely to be complex. Low feedback action by circulating IGF-1 may be involved, particularly at younger ages. Moreover, thc secretion of ncuropeptides modulating GH rclease, such as GH-releasing factor, galanin, somatostatin, dopamine, and activin (21) could be altered, or the presumably different glycosylation state of their respective receptors may result in a nct augmentation of the secretory activity of the somatotroph. The basis for the apparent sexual dimorphism in GH levels is equally uncertain, one possibility being that it is linked to the aforementioned dimorphism of gonadotropin secretion and action.
In the index cases, the glycemic response to glucagon was normal at all examined ages, but the concomitant insulin response was of a striking magnitude during adolescence, whereas the latter was not the case at the age of 2 y. Thcsc observations are indicative of a gradually developing insulin resistance, possibly related to inappropriate glycosylation of the insulin rcceptor. It is noteworthy that the association of insulin resistancc and hypergonadotropic hypogonadism was apparently first noted in 1956 by Dr. Bassoe in his report on a female and a male adult with "familial congenital muscular dystrophy," born in the late 1920s in Norway (22) . Interestingly, the details and illustrations in this publication today permit one to infer credibly that these adults suffered in fact from the CDG syndrome type 1 and, therefore, that this rcport rcpresents the first clinical and endocrinologic dcscription of thc CDG syndromc type 1 in the adult.
The profound alterations in the endocrine homeostasis of children with thc CDG syndromc type 1 point to the vital importance of glycoprotein glycosylation in the endocrine physiology of the human between birth and adulthood. In addition, the unique endocrine paradigm observed in the CDG syndrome type 1 may offer novel insights into the pathogcncsis of hitherto enigmatic conditions. For example, first, it is now plausible that the hypergonadotropic hypogonadism in female adults with galactosemia (23)-which is a secondary CDG syndrome (2, 24)-is equally based on a glycosylation defect. Second, fcmale adolescents with the CDG syndrome type 1 were found to present a picture including an augmented ratio of LHIFSH effect, anovulation, hirsutism, hyperprolactinemia, and insulin resistance, a constellation reminiscent of the polycystic ovary syndrome (25) . The intriguing parallelism between endocrine characteristics of a glycosylation disorder and of polycystic ovary syndrome deserves further investigation.
